Celgene Corporation

CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN FOR USE IN TREATING MYELOMA

#2 | 2026-04-30

US20260115287A1

T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT

#3 | 2026-02-12

US20260042840A1

METHODS OF TREATING TUMOR

#4 | 2025-11-13

US20250345432A1

METHOD FOR PREDICTING RESPONSE TO A T CELL THERAPY

#5 | 2025-10-02

US20250302954A1

METHODS TO OVERCOME DRUG RESISTANCE BY RE-SENSITIZING CANCER CELLS TO TREATMENT WITH A PRIOR THERAPY VIA TREATMENT WITH A T CELL THERAPY

#6 | 2025-09-25

US20250295771A1

METHODS AND USES RELATED TO T CELL THERAPY AND PRODUCTION OF SAME

#7 | 2025-06-12

US20250188545A1

METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA

#8 | 2025-04-17

US20250123281A1

USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

#9 | 2025-01-30

US20250032502A1

METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES

#10 | 2025-01-07 ✅ Patent 12,186,370 granted on 2025-01-07

US17519305

ACTRIIB ligand trap compositions and uses thereof

#11 | 2024-11-28

US20240389562A1

TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON

#12 | 2024-11-07 ✅ Patent 12,404,241 granted on 2025-09-02

US20240368083A1

SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

#13 | 2024-10-24 ✅ Patent 12,343,346 granted on 2025-07-01

US20240350509A1

SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

#14 | 2024-09-12

US20240299570A1

COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI)

#15 | 2024-07-25 ✅ Patent 12,435,028 granted on 2025-10-07

US20240246899A1

PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE

#16 | 2024-07-11

US20240228667A9

Methods for Treating Multiple Myeloma

#17 | 2024-06-27

US20240207310A1

COMBINATION THERAPIES WITH BCMA-DIRECTED T CELL THERAPY

#18 | 2024-04-25

US20240132623A1

Methods for Treating Multiple Myeloma

#19 | 2024-04-18

US20240124444A1

Heterocyclic Compounds and Their Use for Parasitic Diseases

#20 | 2024-04-18 ✅ Patent 12,624,003 granted on 2026-05-12

US20240124394A1

Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases

#21 | 2024-04-04

US20240109881A1

Heteroaryl Compounds as Ligand Directed Degraders of IRAK4

#22 | 2024-02-29 ✅ Patent 12,064,427 granted on 2024-08-20

US20240066026A1

Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

#23 | 2024-02-01 ✅ Patent 12,084,499 granted on 2024-09-10

US20240034789A1

SIRP-α binding proteins and methods of use thereof

#24 | 2024-01-25 ✅ Patent 12,404,239 granted on 2025-09-02

US20240025851A1

Modulators of BCL6 as Ligand Directed Degraders

#25 | 2024-01-18

US20240016936A1

USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS

#26 | 2023-12-14

US20230398149A1

CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY

#27 | 2023-11-30 ✅ Patent 12,410,133 granted on 2025-09-09

US20230382861A1

CRYSTALLINE (R)-5-CARBAMOYLPYRIDIN-3-YL-2-METHYL-4-(3-(TRIFLUOROMETHOXY)BENZYL)PIPERAZINE-1-CARBOXYLATE, COMPOSITIONS AND METHODS OF USE THEREOF

#28 | 2023-11-02 ✅ Patent 12,227,490 granted on 2025-02-18

US20230348431A1

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

#29 | 2023-10-26 ✅ Patent 12,510,533 granted on 2025-12-30

US20230341375A1

METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE

#30 | 2023-10-26 ✅ Patent 12,583,837 granted on 2026-03-24

US20230339901A1

SOLID FORMS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

#31 | 2023-10-19 ✅ Patent 12,186,311 granted on 2025-01-07

US20230330086A1

Antiproliferative compounds and second active agents for combined use

#32 | 2023-09-21

US20230293634A1

ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS

#33 | 2023-09-14 ✅ Patent 12,220,417 granted on 2025-02-11

US20230285400A1

Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

#34 | 2023-09-07 ✅ Patent 12,178,822 granted on 2024-12-31

US20230277548A1

Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion

#35 | 2023-09-07 ✅ Patent 12,605,372 granted on 2026-04-21

US20230277517A1

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

#36 | 2023-08-31 ✅ Patent 12,472,176 granted on 2025-11-18

US20230270742A1

PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME

#37 | 2023-08-17 ✅ Patent 12,053,482 granted on 2024-08-06

US20230255996A1

Oral formulations of cytidine analogs and methods of use thereof

#38 | 2023-08-03 ✅ Patent 12,103,920 granted on 2024-10-01

US20230242509A1

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

#39 | 2023-07-27 ✅ Patent 11,912,644 granted on 2024-02-27

US20230234914A1

Processes for the preparation of ()-tert-butyl 4,5-diamino-5-oxopentanoate

#40 | 2023-06-15 ✅ Patent 12,053,466 granted on 2024-08-06

US20230181575A1

Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use

#41 | 2023-05-25 ✅ Patent 12,396,995 granted on 2025-08-26

US20230158037A1

SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE

#42 | 2023-05-18

US20230149379A1

COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA

#43 | 2023-05-11 ✅ Patent 12,338,235 granted on 2025-06-24

US20230146944A1

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

#44 | 2023-05-11

US20230142386A1

ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING ANEMIA

#45 | 2023-03-30

US20230095912A1

Composition and Methods for Selective Degradation of Engineered Proteins

#46 | 2023-03-02 ✅ Patent 12,474,342 granted on 2025-11-18

US20230064156A1

METHODS FOR TREATING CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES

#47 | 2023-01-26 ✅ Patent 11,919,879 granted on 2024-03-05

US20230028747A1

Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases

#48 | 2023-01-05 ✅ Patent 11,873,283 granted on 2024-01-16

US20230002321A1

Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

#49 | 2022-12-29 ✅ Patent 12,590,953 granted on 2026-03-31

US20220412953A1

METHODS FOR SCREENING CEREBLON MODIFYING COMPOUNDS

#50 | 2022-12-22 ✅ Patent 11,931,420 granted on 2024-03-19

US20220401569A1

Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)

#51 | 2022-12-08

US20220389515A1

USE OF BIOMARKERS TO PREDICT CLINICAL SENSITIVITY TO 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE

#52 | 2022-12-08

US20220387405A1

METHODS OF TREATMENT WITH N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDE

#53 | 2022-12-01

US20220378773A1

METHODS FOR TREATING LEUKEMIA AND USE OF A LEUKEMIC STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPIES

#54 | 2022-11-24

US20220370580A1

CEREBLON-BASED HETERODIMERIZABLE CHIMERIC ANTIGEN RECEPTORS

#55 | 2022-10-27 ✅ Patent 12,428,488 granted on 2025-09-30

US20220340675A1

ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47

#56 | 2022-10-13 ✅ Patent 12,103,923 granted on 2024-10-01

US20220324855A1

Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

#57 | 2022-10-13

US20220323599A1

ANTI-BCMA ANTIBODY CONJUGATE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME

#58 | 2022-09-29 ✅ Patent 11,945,804 granted on 2024-04-02

US20220306611A1

Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith

#59 | 2022-09-15 ✅ Patent 12,391,672 granted on 2025-08-19

US20220289713A1

SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

#60 | 2022-09-08 ✅ Patent 12,029,738 granted on 2024-07-09

US20220280505A1

Antiproliferative compounds and methods of use thereof

#61 | 2022-09-01 ✅ Patent 12,357,633 granted on 2025-07-15

US20220273654A1

METHODS OF TREATING CANCER BY TARGETING COLD TUMORS

#62 | 2022-08-18 ✅ Patent 12,049,470 granted on 2024-07-30

US20220259222A1

MK2 inhibitors, the synthesis thereof, and intermediates thereto

#63 | 2022-08-11

US20220249528A1

AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME

#64 | 2022-07-28 ✅ Patent 11,780,801 granted on 2023-10-10

US20220234990A1

Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein

#65 | 2022-07-07 ✅ Patent 12,486,281 granted on 2025-12-02

US20220213115A1

SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

#66 | 2022-07-07 ✅ Patent 12,577,223 granted on 2026-03-17

US20220213056A1

PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE

#67 | 2022-07-07 ✅ Patent 11,883,389 granted on 2024-01-30

US20220211686A1

Formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

#68 | 2022-05-26 ✅ Patent 12,545,740 granted on 2026-02-10

US20220162330A1

ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47

#69 | 2022-05-26 ✅ Patent 12,227,519 granted on 2025-02-18

US20220162230A1

Preparation of maytansinol

#70 | 2022-05-26 ✅ Patent 12,064,437 granted on 2024-08-20

US20220160720A1

Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies

#71 | 2022-04-28 ✅ Patent 11,655,232 granted on 2023-05-23

US20220127244A1

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

#72 | 2022-03-17 ✅ Patent 11,571,436 granted on 2023-02-07

US20220079964A1

Oral formulations of cytidine analogs and methods of use thereof

#73 | 2022-01-20

US20220017862A1

IMPROVED T CELL MANUFACTURING PROCESS

#74 | 2022-01-13 ✅ Patent 11,660,302 granted on 2023-05-30

US20220008427A1

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

#75 | 2022-01-06

US20220003749A1

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

#76 | 2022-01-06 ✅ Patent 11,560,371 granted on 2023-01-24

US20220002273A1

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

#77 | 2021-12-30 ✅ Patent 11,634,407 granted on 2023-04-25

US20210403454A1

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

#78 | 2021-12-30 ✅ Patent 11,739,075 granted on 2023-08-29

US20210403453A1

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

#79 | 2021-12-30 ✅ Patent 12,215,094 granted on 2025-02-04

US20210403452A1

Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol

#80 | 2021-12-02

US20210371522A1

CD47 ANTIBODIES AND METHODS OF USE THEREOF

#81 | 2021-11-30 ✅ Patent 11,186,556 granted on 2021-11-30

US16653629

Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof

#82 | 2021-11-25 ✅ Patent 11,680,046 granted on 2023-06-20

US20210363105A1

Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof

#83 | 2021-10-28

US20210330788A1

USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

#84 | 2021-10-07 ✅ Patent 11,629,335 granted on 2023-04-18

US20210309966A1

Methods of improving vector transduction efficiency into T lymphocytes

#85 | 2021-09-30 ✅ Patent 11,806,365 granted on 2023-11-07

US20210299175A1

Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis

#86 | 2021-08-19

US20210254003A1

CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT

#87 | 2021-08-19

US20210254000A1

PROCESS FOR PRODUCING A T CELL COMPOSITION

#88 | 2021-07-29 ✅ Patent 12,065,423 granted on 2024-08-20

US20210230136A1

Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof

#89 | 2021-06-17 ✅ Patent 11,726,080 granted on 2023-08-15

US20210181184A1

Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile

#90 | 2021-06-10 ✅ Patent 11,312,699 granted on 2022-04-26

US20210171493A1

Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

#91 | 2021-06-03 ✅ Patent 11,834,675 granted on 2023-12-05

US20210163890A1

T lymphocyte production methods and t lymphocytes produced thereby

#92 | 2021-05-27 ✅ Patent 11,590,117 granted on 2023-02-28

US20210154182A1

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

#93 | 2021-05-06

US20210128619A1

USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

#94 | 2021-05-06 ✅ Patent 11,701,362 granted on 2023-07-18

US20210128564A1

Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide

#95 | 2021-05-06 ✅ Patent 12,090,147 granted on 2024-09-17

US20210128545A1

Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

#96 | 2021-04-29 ✅ Patent 11,524,950 granted on 2022-12-13

US20210122727A1

Treatment of immune-related and inflammatory diseases

#97 | 2021-04-22

US20210116454A1

METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE

#98 | 2021-04-22 ✅ Patent 11,578,056 granted on 2023-02-14

US20210115019A1

Solid forms comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same

#99 | 2021-04-22 ✅ Patent 11,666,579 granted on 2023-06-06

US20210113577A1

Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

#100 | 2021-04-22 ✅ Patent 11,583,536 granted on 2023-02-21

US20210113576A1